{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:18:13Z","timestamp":1787167093168,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.lungcan.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T18:44:40Z","timestamp":1476902680000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials"],"prefix":"10.1016","volume":"102","author":[{"given":"Bob T.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan A.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Khasraw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin M.","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.10.004_bib0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0010","doi-asserted-by":"crossref","first-page":"s4613","DOI":"10.1158\/1078-0432.CCR-07-0647","article-title":"Bevacizumab in non small cell lung cancer","volume":"13","author":"Sandler","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0015","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0025","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0030","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00228-012-1333-3","article-title":"Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials","volume":"69","author":"Xiao","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0045","doi-asserted-by":"crossref","first-page":"e109757","DOI":"10.1371\/journal.pone.0109757","article-title":"Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses","volume":"9","author":"Liang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0050","doi-asserted-by":"crossref","first-page":"e0127306","DOI":"10.1371\/journal.pone.0127306","article-title":"The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis","volume":"10","author":"Sheng","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0055","series-title":"Handbook for Systematic Reviews of INterventions Version 5 0.1. The Cochrane Collaboration","author":"Higgins","year":"2011"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0060","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/1471-2407-14-290","article-title":"Randomized phase II study of pemetrexed\/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer","volume":"14","author":"Belani","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/JTO.0b013e318274a85d","article-title":"A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528","volume":"8","author":"Dy","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2009.22.9427","article-title":"Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study","volume":"28","author":"Goss","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0075","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1200\/JCO.2008.17.3138","article-title":"Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer","volume":"26","author":"Heymach","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0080","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejca.2013.11.032","article-title":"Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29","volume":"50","author":"Laurie","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0085","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2011.39.7646","article-title":"Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine\/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer","volume":"30","author":"Paz-Ares","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2014.55.7173","article-title":"Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer","volume":"33","author":"Ramalingam","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0095","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","article-title":"Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer","volume":"28","author":"Scagliotti","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0100","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1200\/JCO.2011.41.4987","article-title":"International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin\/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1","volume":"30","author":"Scagliotti","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0105","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","article-title":"Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial","volume":"29","author":"de Boer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0110","first-page":"31","article-title":"Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy","author":"Hanna","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JTO.0000000000000071","article-title":"CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer","volume":"9","author":"Heist","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0120","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0125","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2006.10.5122","article-title":"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer","volume":"25","author":"Heymach","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0135","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/JTO.0000000000000227","article-title":"Motesanib plus carboplatin\/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study","volume":"9","author":"Novello","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0140","first-page":"29","article-title":"A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study","author":"Molina","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0145","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/JTO.0000000000000120","article-title":"Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients","volume":"9","author":"Gridelli","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0150","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0155","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0160","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0165","article-title":"Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer","author":"Falchook","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0170","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/JTO.0b013e31828a4d07","article-title":"A patient with lung adenocarcinoma and RET fusion treated with vandetanib","volume":"8","author":"Gautschi","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0180","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2016.10.004_bib0185","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216304895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216304895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T07:53:40Z","timestamp":1536306820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216304895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":37,"alternative-id":["S0169500216304895"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.10.004","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}